Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jon Hartas"'
Autor:
Silvana Sekuloski, Michael R Batzloff, Paul Griffin, William Parsonage, Suzanne Elliott, Jon Hartas, Peter O'Rourke, Louise Marquart, Manisha Pandey, Fran A Rubin, Jonathan Carapetis, James McCarthy, Michael F Good
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0198658 (2018)
BACKGROUND:Group A streptococcus (GAS) is a serious human pathogen that affects people of different ages and socio-economic levels. Although vaccination is potentially one of the most effective methods to control GAS infection and its sequelae, few p
Externí odkaz:
https://doaj.org/article/7500b34fc68343af9bc2752daec7d8cd
Autor:
James S. McCarthy, Ainslie Calcutt, Michael R. Batzloff, Catherine M. Rush, Jon Hartas, Natkunam Ketheesan, Manisha Pandey, Davina Gorton, Linda K. Johnson, Grace Yeung, Tania Rivera-Hernandez, Michael F. Good, Anne Fane
Publikováno v:
Human Vaccines & Immunotherapeutics. 12:3089-3096
Streptococcus pyogenes (group A streptococcus, GAS) causes a wide range of clinical manifestations ranging from mild self-limiting pyoderma to invasive diseases such as sepsis. Also of concern are the post-infectious immune-mediated diseases includin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3db3de4ee9f933833ba8d0d36d54c62
https://doi.org/10.1080/21645515.2016.1222999
https://doi.org/10.1080/21645515.2016.1222999
Autor:
Jonathan R. Carapetis, Jon Hartas, Suzanne L. Elliott, Paul M. Griffin, Manisha Pandey, Fran A. Rubin, James S. McCarthy, Silvana Sekuloski, Michael R. Batzloff, Louise Marquart, Peter O'Rourke, William A. Parsonage, Michael F. Good
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 7, p e0198658 (2018)
PLoS ONE, Vol 13, Iss 7, p e0198658 (2018)
BACKGROUND:Group A streptococcus (GAS) is a serious human pathogen that affects people of different ages and socio-economic levels. Although vaccination is potentially one of the most effective methods to control GAS infection and its sequelae, few p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6373e5ea40b652d7795965254ae753ee
http://europepmc.org/articles/PMC6028081
http://europepmc.org/articles/PMC6028081
Autor:
Zhongfan Jia, Jon Hartas, Mariusz Skwarczynski, I-Chun Lin, Abdullah Ah Ahmad Fuaad, Michael F. Good, Istvan Toth, Michael J. Monteiro, Peter M. Moyle, Zyta M. Ziora, Mehfuz Zaman, Michael R. Batzloff
Publikováno v:
Nanomedicine. 9:35-43
Aim: To explore four-arm star poly(t-butyl)acrylate (PtBA)–peptide and linear PtBA–peptide conjugates as a vaccine-delivery system against Group A Streptococcus. Materials & methods: PtBA nanoparticles bearing J14 peptide epitopes were prepared v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::495668997afe39dce53b40655d3c869c
https://doi.org/10.2217/nnm.13.7
https://doi.org/10.2217/nnm.13.7
Autor:
Jon Hartas, Yang Wu, Tania Rivera-Hernandez, Yap P. Chuan, Michael F. Good, Anton P. J. Middelberg, Linda H.L. Lua, Michael R. Batzloff
Publikováno v:
Vaccine. 31:1950-1955
Group A streptococcus (GAS) causes a wide range of diseases, some of them related to autoimmune diseases triggered by repeated GAS infections. Despite the fact that GAS primarily colonizes the mucosal epithelium of the pharynx, the main mechanism of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde0f5906c476e5498d803d0cf5eac3b
https://doi.org/10.1016/j.vaccine.2013.02.013
https://doi.org/10.1016/j.vaccine.2013.02.013
Autor:
Jason N. Cole, Marcus Fulde, Bostjan Kobe, Anna Henningham, Emiliano Chiarot, K.S. Sriprakash, Amanda J. Cork, Immaculada Margarit, Graham Magor, Steven P. Djordjevic, Stuart J. Cordwell, Manfred Rohde, Mark J. Walker, Victor Nizet, Christine M. Gillen, Jon Hartas, Michael R. Batzloff, G. S. Chhatwal, Vidiya Ramachandran
Publikováno v:
Journal of Molecular Medicine. 90:1197-1207
Streptococcus pyogenes (group A Streptococcus (GAS)) causes ∼700 million human infections each year, resulting in over 500,000 deaths. The development of a commercial GAS vaccine is hampered by the occurrence of many unique GAS serotypes, antigenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::794ab20132697185aac3a96d6366ebc3
https://doi.org/10.1007/s00109-012-0897-9
https://doi.org/10.1007/s00109-012-0897-9
Autor:
Alfred King-Yin Lam, Michael R. Batzloff, Emma L. Langshaw, Manisha Pandey, Michael F. Good, Jon Hartas
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 194(12)
Infections caused by Streptococcus pyogenes (group A Streptococcus [GAS]) are highly prevalent in the tropics, in developing countries, and in the Indigenous populations of developed countries. These infections and their sequelae are responsible for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49481226fc27eb7f6c0d45b3ae6059ee
https://pubmed.ncbi.nlm.nih.gov/25980008
https://pubmed.ncbi.nlm.nih.gov/25980008
Autor:
Tomas Leanderson, Jon Hartas, Michael R. Batzloff, Mark R. Davies, Gregory L. White, Michael F. Good, George H. Lowell, Huaru Yan, David S. Burt
Publikováno v:
The Journal of Infectious Diseases. 192:1450-1455
Infection with group A streptococcus (GAS) may result in a number of clinical conditions, including the potentially life-threatening postinfectious sequelae of rheumatic fever and rheumatic heart disease. As part of the search for a vaccine to preven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8622758c441033cff8ad9ef76122662e
https://doi.org/10.1086/466528
https://doi.org/10.1086/466528
Streptococcus pyogenes (group A Streptococcus [GAS]) is a leading human pathogen associated with a diverse array of mucosal and systemic infections. Vaccination with J8, a conserved region synthetic peptide derived from the M-protein of GAS and conta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d30fe5c16ee3aa0f9f85fb8d69d2e61
https://europepmc.org/articles/PMC3594626/
https://europepmc.org/articles/PMC3594626/
Autor:
Peter M. Moyle, Jon Hartas, Michael F. Good, Anna Henningham, Istvan Toth, Michael R. Batzloff
Publikováno v:
Nanomedicine : nanotechnology, biology, and medicine. 9(7)
A novel vaccine development platform that enables the site-specific conjugation of synthetic lipid adjuvants to recombinant proteins was produced. This technology facilitates the simple and efficient production of homogeneous, chemically-defined, sem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f8ec4cf78b436ded7168562e04ee5f
https://pubmed.ncbi.nlm.nih.gov/23428988
https://pubmed.ncbi.nlm.nih.gov/23428988